Literature DB >> 32146004

Prognostic impact of lncRNA-ATB expression in malignant solid tumors: A meta-analysis.

Bolin Wang1, Zhong Lu2, Yan Huang3, Tao Lin1.   

Abstract

PURPOSE: Numerous studies have reported the prognostic role of lncRNA-ATB high expression in solid tumours, but its prognostic effect is still uncertain. Therefore, the purpose of this meta-analysis was to further comprehensively verify the prognostic role of the lncRNA-ATB high expression in solid tumours.
METHODS: A literature search was performed using the electronic platforms to obtain relevant research studies published up to 31 May 2019. Confidence intervals of research endpoints in each study were extracted and merged. All data analysis was performed using Stata12.0 software.
RESULTS: A total of 2120 patients with solid cancers in 14 studies were enrolled in our meta-analysis eventually. The analysis results revealed that high expression of lncRNA-ATB was related to lower OS (HR:1.46, P < 0.001), shorter DFS(HR:1.73, P < 0.001), and earlier RFS (HR:2.67, P < 0.001). Besides, the high expression of lncRNA-ATB has a considerable risk of lymph node metastasis (OR:2.13, P = 0.017)and perineural invasion (OR:1.58, P = 0.018).
CONCLUSIONS: Meta-analysis showed that the high lncRNA-ATB expression was a poor prognostic marker in multiple cancer types. The high expression of lncRNA-ATB symbolizes the high risk of lymph node metastasis and perineural invasion in cancer patients.
Copyright © 2020 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Cancer; Meta-analysis; Prognosis; Solid tumors; lncRNA-ATB

Mesh:

Substances:

Year:  2020        PMID: 32146004     DOI: 10.1016/j.prp.2020.152897

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  1 in total

1.  Association between Alpha B-crystallin expression and prognosis in patients with solid tumors: A protocol for systematic review and meta-analysis.

Authors:  Minglan Yang; Yufan Li; Feng Tian
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.